Latest Molecular Diagnostics Technology Aids German Hospital in Management of European E. coli Crisis

By Luminexkliniken Der Stadt Kln Institute Of Pathology And Institute For Hygiene, PRNE
Tuesday, June 7, 2011

AUSTIN, Texas and KOLN, Germany, June 8, 2011 -

- New CE Marked xTAG(R) Gastrointestinal Pathogen Panel (GPP) Used to
Triage Patients at German Kliniken der Stadt Koln

Luminex Corporation (NASDAQ: LMNX) and the Kliniken der Stadt Koln,
Institute of Pathology and Institute for Hygiene today announced that
Luminex's newly released xTAG(R) Gastrointestinal Pathogen Panel (GPP) is
being used successfully as a first-line screen for patients at Kliniken der
Stadt Koln suspected of having an E. coli infection. This includes the
detection of hemolytic-uremic syndrome (HUS) causing Shiga-like toxin
producing E. coli strain responsible for the current outbreak.


Kliniken der Stadt Koln Institut fur Pathologie worked with Luminex last
week to quickly implement this new diagnostic assay when they successfully
showed xTAG GPP was able to accurately detect the outbreak pathogens in
patient samples.

As of 7 June at 15:00 CET World Health Organization (WHO) reported 2,745
people in 12 European countries have been sickened by E. coli. Since the
beginning of May, there have been 722 notified cases of HUS and 25 deaths -
nineteen fatalities resulting from HUS infections and six fatalities from E.
coli non-HUS infections. Staff at Kliniken der Stadt Koln Institut fur
Pathologie, who use the Luminex xTAG Respiratory Viral Panel (RVP), have
quickly adopted xTAG GPP as an important first line screen to help manage the
current outbreak in Germany.

Since xTAG GPP can rapidly and simultaneously identify 95% of acute
gastroenteritis pathogens, infected patients can be quickly identified and
appropriately managed. Positive STEC patients can be closely monitored and
treated in parallel with confirmatory testing. Additionally, patients who are
infected with other causative infectious agents; or those who are negative,
can be quickly identified and receive appropriate care or be discharged, thus
making healthcare resources available to those most in need.

"Prior to the approval last month of xTAG GPP, we did not have a test
that would allow us to rapidly detect a comprehensive array of
disease-causing pathogens for infectious gastroenteritis," said PD Dr. Frauke
, of Kliniken der Stadt, Institute of Pathology and Institute for
Hygiene. "The ability of xTAG GPP to detect not only several different types
of E. coli, but also the presence of the Stx-2 gene, a key marker of this
more severe STEC strain, is allowing rapid identification of patients who may
be suffering from an infection of this outbreak strain. This innovative
technology is an important advance and an invaluable tool in the management
of the current crisis."

"We are pleased and proud that our new innovative assay, xTAG GPP, is
helping health care professionals in Germany rapidly identify patients who
may be infected with this pathogen and is assisting them during this crisis,"
said Patrick J. Balthrop, president and CEO of Luminex. "All of my Luminex
colleagues across the globe share a serious concern for those affected and
hope for a resolution to the current situation as quickly as possible."

About xTAG Gastrointestinal Pathogen Panel (GPP)

Luminex's xTAG GPP can simultaneously detect fifteen of the most common
disease-causing gastrointestinal pathogens, including viruses, bacteria and
parasites, such as E. coli, Campylobacter, Salmonella and C. difficile all
within 5 hours. xTAG GPP received CE mark approval in May of 2011 from
European regulatory authorities and is now being used as an important aid for
patient triage in the current outbreak.

More information on Luminex and xTAG GPP can be found at , or Luminex's European office at, Krombraak
15, 4906 CR Oosterhout, The Netherlands, +

About Kliniken der Stadt Koln, Institute of Pathology and Institute for

Kliniken der Stadt Koln gGmbH is a network of urban hospitals that
includes the hospitals in Cologne-Merheim and Cologne-Holweide as well as the
Amsterdamer StraBe pediatric hospital. With more than 1,500 beds, the
hospital group is the largest provider of inpatient health services in
Cologne. Approximately 4,000 staff members treat, care for and handle about
60,000 patients per year on an inpatient basis, and more than twice as many
on an outpatient basis. With annual revenues of roughly 280 million euros,
the network is one of the large urban hospitals in Germany. Kliniken der
Stadt Koln gGmbH is run by CEO Prof. Christian Schmidt, MD and MPH, and Roman
Lovenfosse-Gehrt. Research teaching is a top priority at Kliniken der Stadt
Koln gGmbH: the three urban hospitals are teaching hospitals of the
University of Cologne; the hospital at Cologne-Merheim is a clinical center
of the University of Witten/Herdecke.

About Luminex Corporation

Luminex Corporation develops, manufactures and markets proprietary
biological testing technologies with applications throughout the diagnostic
and life sciences industries. The company's xMAP multiplex solutions include
an open-architecture, multi-analyte technology platform that delivers fast,
accurate and cost-effective bioassay results to markets as diverse as
pharmaceutical drug discovery, clinical diagnostics and biomedical research,
including genomic and proteomic research markets. The company's xMAP
technology is sold worldwide and is already in use in leading clinical
laboratories as well as major pharmaceutical, diagnostic and biotechnology
companies. Further information on Luminex Corporation or xMAP technology can
be obtained at


    Matt Scalo
    Luminex Corporation

    Mimi Torrington
    Luminex Corporation

    Jana Stoudemire
    Porter Novelli

    Hugo Beeckmans
    Porter Novelli - EU

    PD Dr. Oliver
    Kliniken der Stadt Koln
    Ostmerheimer Strasse 200,
    51109 Koln, Cologne, Germany

    PD Dr. Frauke Mattner
    Kliniken der Stadt Koln
    Ostmerheimer Strasse 200
    51109 Koln, Cologne, Germany


will not be displayed